title: Immunotherapy with tumor vaccines for the treatment of malignant gliomas.
abstract: With an average life expectancy of 14 months, Glioblastoma multiforme (GBM), is the most aggressive primary brain tumor. Our growing understanding of the immune system and its role in oncogenesis has helped develop cancer vaccines as a promising treatment modality against this disease. What follows is a comprehensive discussion on the history of immunotherapy and the various vaccine based therapies being developed and utilized for the treatment of malignant gliomas.
authors.affiliation: Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA. divyaajay@nus.edu.sg
authors.forename: Divya
authors.initials: D
authors.lastname: Ajay
authors.forename: Luis
authors.initials: L
authors.lastname: Sanchez-Perez
authors.forename: Bryan D
authors.initials: BD
authors.lastname: Choi
authors.forename: Gabriel
authors.initials: G
authors.lastname: De Leon
authors.forename: John H
authors.initials: JH
authors.lastname: Sampson
mesh_terms: D001932:Brain Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005909:Glioblastoma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy
chemical_list: D019496:Cancer Vaccines